HSYHIGH SIGNALFINANCIAL10-K

Hershey experienced a substantial decline in profitability with net income falling meaningfully and operating income dropping roughly in half year-over-year.

The dramatic deterioration in profitability signals significant operational challenges or one-time charges that materially impacted earnings performance. The concurrent reduction in gross profit margins suggests either cost pressures, pricing headwinds, or potential restructuring activities that compressed the company's core profitability metrics.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

Hershey's financial performance deteriorated substantially, with both net income and operating income declining meaningfully while gross profit fell 26%. The company's balance sheet showed some positive developments with cash and equivalents increasing 54.7% and current liabilities decreasing 23.4%, suggesting improved liquidity management. However, the sharp decline in profitability metrics alongside reduced capital expenditure (-25%) indicates either significant one-time charges or underlying operational challenges that warrant close investor scrutiny.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-60.2%
$2.2B→$883.3M

Net income declined 60.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+54.7%
$380.2M→$588.0M

Cash position surged 54.7% — strong cash generation or capital raise providing significant financial cushion.

Operating Income
P&L
-50.3%
$2.9B→$1.4B

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Interest Expense
P&L
+29%
$174.3M→$224.8M

Interest costs rose 29% — monitor debt levels and coverage ratio in rising rate environment.

Gross Profit
P&L
-26%
$5.3B→$3.9B

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Capital Expenditure
Cash Flow
-25%
$605.9M→$454.6M

Capex reduced 25% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Liabilities
Balance Sheet
-23.4%
$3.9B→$3.0B

Current liabilities reduced — improved short-term financial position and working capital health.

Inventory
Balance Sheet
+14%
$1.3B→$1.4B

Inventory built 14% — monitor whether demand supports this build or if write-downs may follow.

Total Liabilities
Balance Sheet
+10.6%
$8.2B→$9.1B

Liabilities increased 10.6% — monitor debt-to-equity ratio and interest coverage.

R&D Expense
P&L
+10.5%
$55.8M→$61.7M

R&D investment increased 10.5% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
Determination of aggregate market value assumes all outstanding shares of Class B Common Stock held by non-affiliates were converted to Common Stock as of June 27, 2025.
The market value indicated is calculated based on the closing price of the Common Stock on the New York Stock Exchange on June 27, 2025 ($ 166.99 per share).
Common Stock, one dollar par value 148,077,438 shares, as of February 12, 2026.
Class B Common Stock, one dollar par value 54,613,514 shares, as of February 12, 2026.
We market, sell, and distribute our products under more than 85 brand names in approximately 65 countries worldwide.
+7 more — sign up free →
REMOVED
Determination of aggregate market value assumes all outstanding shares of Class B Common Stock held by non-affiliates were converted to Common Stock as of June 28, 2024.
The market value indicated is calculated based on the closing price of the Common Stock on the New York Stock Exchange on June 28, 2024 ($ 183.83 per share).
Common Stock, one dollar par value 147,797,121 shares, as of February 10, 2025.
Class B Common Stock, one dollar par value 54,613,514 shares, as of February 10, 2025.
We market, sell and distribute our products under more than 90 brand names in approximately 70 countries worldwide.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →